Connection
Michael Kahn to Imatinib Mesylate
This is a "connection" page, showing publications Michael Kahn has written about Imatinib Mesylate.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.735 |
|
|
|
-
Zhao Y, Wu K, Wu Y, Melendez E, Smbatyan G, Massiello D, Kahn M. Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Curr Mol Pharmacol. 2018; 11(2):113-121.
Score: 0.533
-
Chimge NO, Chen MH, Nguyen C, Zhao Y, Wu X, Gonzalez PG, Ogana H, Hurwitz S, Teo JL, Chen X, Du J, Jin V, Kim YM, Ono M, Argüello RJ, Kahn M. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I. Curr Mol Pharmacol. 2024; 17:e060923220758.
Score: 0.202